+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Reduced Serum and Cerebrospinal Fluid Levels of Autotaxin in Major Depressive Disorder



Reduced Serum and Cerebrospinal Fluid Levels of Autotaxin in Major Depressive Disorder



International Journal of Neuropsychopharmacology 22(4): 261-269



The autotaxin/lysophosphatidic acid axis is involved in diverse biological processes including neurodevelopment, inflammation, and immunological functioning. The lysophosphatidic acid 1 receptor has been implicated in the pathophysiology of major depressive disorder and in the mechanism of action of antidepressants. However, it is unclear whether central or peripheral autotaxin levels are altered in patients with major depressive disorder. Serum autotaxin levels were measured by an enzyme-linked immunosorbent assay in 37 patients with major depressive disorder diagnosed using DSM-IV-TR who underwent electroconvulsive therapy and were compared with those of 47 nondepressed controls matched for age and sex between January 2011 and December 2015. Patient serum levels of autotaxin before and after electroconvulsive therapy were also compared. In a separate sample set, cerebrospinal fluid autotaxin levels were compared between 26 patients with major depressive disorder and 27 nondepressed controls between December 2010 and December 2015. A potential association was examined between autotaxin levels and clinical symptoms assessed with the Hamilton Depression Rating Scale. Before electroconvulsive therapy, both serum and cerebrospinal fluidautotaxin levels were significantly lower in major depressive disorder patients than in controls (serum: P = .001, cerebrospinal fluid: P = .038). A significantly negative correlation between serum, but not cerebrospinal fluid, autotaxin levels and depressive symptoms was observed (P = .032). After electroconvulsive therapy, a parallel increase in serum autotaxin levels and depressive symptoms improvement was observed (P = .005). The current results suggest that serum autotaxin levels are reduced in a state-dependent manner. The reduction of cerebrospinal fluidautotaxin levels suggests a dysfunction in the autotaxin/lysophosphatidic acid axis in the brains of patients with major depressive disorder.

(PDF emailed within 0-6 h: $19.90)

Accession: 066456326

Download citation: RISBibTeXText

PMID: 30715387

DOI: 10.1093/ijnp/pyz005


Related references

Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology 17(9): 573-579, 2007

Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. Comprehensive Psychiatry 68: 34-39, 2017

Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia. Biochemical and Biophysical Research Communications 497(2): 683-688, 2018

Plasma and cerebrospinal fluid G72 protein levels in schizophrenia and major depressive disorder. Psychiatry Research 254: 244-250, 2017

Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with clinical variables in patients with schizophrenia, bipolar disorder, and major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 76: 12-18, 2017

Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. Journal of Psychiatric Research 47(3): 401-406, 2014

Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. Plos One 10(3): E0121975, 2016

Increased cerebrospinal fluid fibrinogen levels in major depressive disorder replicated in a larger sample set. European Neuropsychopharmacology 26: S403-S404, 2016

Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE), but not S100B in major depressive disorder. World Journal of Biological Psychiatry 16(2): 106-113, 2015

Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder. Journal of Clinical Psychiatry 78(8): E947-E956, 2017

Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients. Journal of Affective Disorders 232: 134-138, 2018

Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers. Arquivos de Neuro-Psiquiatria 71(9b): 689-692, 2014

Cerebrospinal fluid D-serine concentrations in major depressive disorder negatively correlate with depression severity. Journal of Affective Disorders 226: 155-162, 2017

Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. Expert Review of Proteomics 14(6): 499-514, 2017

Serum ghrelin levels and the effects of antidepressants in major depressive disorder and panic disorder. Neuropsychobiology 66(3): 185-192, 2013